Heidelberg University
Clinical trials sponsored by Heidelberg University, explained in plain language.
-
Heart drug study halted early: what it means for lung patients
Disease control TerminatedThis study looked at whether the drug riociguat could improve right heart size and function in people with two types of pulmonary hypertension (PAH and CTEPH). It enrolled 30 adults and used echocardiograms to measure changes. The study was terminated early, so the results are li…
Phase: PHASE4 • Sponsor: Heidelberg University • Aim: Disease control
Last updated May 17, 2026 03:59 UTC
-
Early intervention trial for lung blood vessel disease halted
Disease control TerminatedThis study aimed to see if a drug called riociguat could help people with early-stage pulmonary vascular disease, a condition that can lead to high blood pressure in the lungs. It involved 35 adults with connective tissue diseases like scleroderma who had mildly elevated lung pre…
Phase: PHASE2 • Sponsor: Heidelberg University • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC